EcoDrugPlus

Proteasome 26s Subunit, Atpase 6

Ensembl ID : ENSLCAG00010011985
Gene Symbol: PSMC6
1 Cross references
242 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 1

Ensembl ID : ENSLCAG00010011074
Gene Symbol: LOC108881246
4 Cross references
214 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 11

Ensembl ID : ENSLCAG00010017874
Gene Symbol: PSMD11
2 Cross references
207 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 12

Ensembl ID : ENSLCAG00010025136
Gene Symbol: PSMD12
1 Cross references
220 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 13

Ensembl ID : ENSLCAG00010004257
Gene Symbol: LOC108894167
4 Cross references
216 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 14

Ensembl ID : ENSLCAG00010008010
Gene Symbol: LOC108887970
4 Cross references
214 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 6

Ensembl ID : ENSLCAG00010009582
Gene Symbol: LOC108899665
4 Cross references
212 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 7

Ensembl ID : ENSLCAG00010013085
Gene Symbol: PSMD7
1 Cross references
235 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 8

Ensembl ID : ENSLCAG00010005812
Gene Symbol: LOC108876133
4 Cross references
211 Possible Orthologues:

Proteasome Subunit Beta 11

Ensembl ID : ENSLCAG00010007390
Gene Symbol: PSMB11
4 Cross references
169 Possible Orthologues:

Proteasome Subunit Beta Type-8

Ensembl ID : ENSLCAG00010009282
Gene Symbol: LOC108888424
4 Cross references
217 Possible Orthologues:

Proteasome Subunit Beta Type-8

Ensembl ID : ENSLCAG00010020848
Gene Symbol: LOC108881903
4 Cross references
217 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).